Antidiabetic
Phase 2Small molecule
Antidiabetic is one of 120 small molecule programs targeting Diabetic Nephropathy. It is currently in Phase 2.
3
Indications
6
Total Trials
2
Active Trials
119
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
198 competitors in Heart Failure
#DrugCompanyPhaseTrials
1Bayer Aspirin
BayerPreclinical
Brethine
SanofiPreclinical
Medrol
PfizerPreclinical
Antidiabetic
FFederico II University
Phase 2
Activase
RochePreclinical
Zemplar
AbbViePreclinical
Adriamycin
PfizerPreclinical
Savaysa
Daiichi SankyoPreclinical
Xylocaine
MMEDRx USA, Inc.
Preclinical
Tamiflu
CConrado Roberto Hoffmann Filho
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Diabetic Nephropathy2 trials
Magnesium Supplementation in Diabetic Nephropathy
Completed·—·Phase 2·NCT03824379·60 enrolled
Heart Failure1 trial
Osteoarthritis1 trial
GLP1 Analogues and the Risk of Osteoarthritis
Not yet recruiting·—··NCT07360457·390 enrolled
Non-Alcoholic Fatty Liver Disease1 trial
Nicotinamide in Non-Alcoholic Fatty Liver Disease Patients
Completed·—·Phase 2·NCT03850886·61 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Antidiabetic. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- FFederico II University